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Abstract
Burkitt’s lymphoma (BL), an EBV-associated tumour, occurs at high incidence in populations where malaria is holoendemic.
Previous studies in one such population suggested that acute P.falciparum infection impairs EBV-specific T-cell surveillance,
allowing expansion of EBV infected B-cells from which BL derives. We re-examined the situation in the same area, The
Gambia, after a reduction in malaria endemicity. Cellular immune responses to EBV were measured in children with
uncomplicated malaria before (day 0) and after treatment (day 28), comparing EBV genome loads in blood and EBV-specific
CD8
+ T-cell numbers (assayed by MHC Class I tetramers and IFNc ELISPOTS) with those seen in age- and sex-matched
healthy controls. No significant changes were seen in EBV genome loads, percentage of EBV-specific CD8
+ T-cells and IFNc
producing T-cells in acute versus convalescent samples, nor any difference versus controls. Regression assays performed
also no longer detected any impairment of EBV-specific T-cell surveillance. Acute uncomplicated malaria infection no longer
alters EBV-specific immune responses in children in The Gambia. Given the recent decline in malaria incidence in that
country, we hypothesise that gross disturbance of the EBV-host balance may be a specific effect of acute malaria only in
children with a history of chronic/recurrent malaria challenge.
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Introduction
EBV is a gamma herpesvirus, ubiquitous in human populations,
that is usually acquired early in life by the oral route, replicates
locally through a virus productive (lytic) infection at oropharyngeal
sites and is carried thereafter for life as a latent, largely
asymptomatic, infection of the B-cell pool [1,2]. Yet this apparently
innocuous agent has potent growth-transforming ability for its
principal target cell, the B lymphocyte,and is linkedto severalB-cell
malignancies especially in immunosuppressed hosts [3].
Indeed EBV first colonises the B-cell system through a growth-
transforming infection, where coordinate expression of specific
latent cycle genes drives the expansion of infected B-cell clones.
These expansions are controlled by the EBV-specific T-cell
response but it appears that some infected cells survive by
extinguishing latent gene expression, thereby generating a reservoir
of latently infected, resting B-cells through which the virus persists
[1]. Reactivations from this reservoir do nevertheless occur and, if
not controlled by virus-specific T-cells, can lead to further B-cell
transformation events and greatly increased loads of latently-
infected B-cellsintheblood [4].In theWest, this is most apparentin
heavily T-cell suppressed transplant patients, where high circulating
EBV loads often precede the appearance of EBV-positive post-
transplant lymphoproliferative disease (PTLD) [5,6]. A somewhat
analogous situation is thought to occur in Africa, where the similar
geographic distributions of Burkitt Lymphoma (BL), an EBV-
associated childhood tumour, and of holoendemic malaria suggests
that malaria may predispose to BL through suppression of T-cell
surveillance leading to increased viral loads [7].
Several studies have indeed implied that malaria exposure can
cause a reduction in EBV-specific T-cell responses [8]. Early
assays quantifying the regression of EBV-infected B-cell outgrowth
in peripheral blood mononuclear cell cultures, an effect mediated
by in vitro reactivation of EBV latent antigen-specific CD8
+
cytotoxic T-cells [9], showed a slight relaxation of T-cell control in
healthy adults from holoendemic malarial versus non-endemic
malarial areas of New Guinea [10]. Subsequently a study of
healthy children in Kenya with differential malaria exposure has
shown that a smaller proportion of children, five to nine years of
age, had EBV-specific IFN-c ELISPOT responses (PBMC), when
living in malaria-holoendemic areas, compared to those living in
areas where exposure is only sporadic [11]. EBV genome loads in
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holoendemic malaria group, but only in children one to four years
of age [12]. Turning to acute malaria itself, T-cell control as
measured by the regression assay appeared to be completely
abrogated in children from a holoendemic area, The Gambia,
during an episode of acute malaria, but recovered to some extent
after treatment and the resolution of symptoms [8,13]. More
recently EBV-specific CD8
+ T-cell responses restricted through
two HLA alleles, B*3501 and B*5301, were measured by IFN-c
ELISPOT in Gambian children with acute malaria and compared
to results obtained up to 6 weeks post-treatment. With the caveat
of a small sample size in mind, this comparison suggested that
responses were impaired during acute disease, but it was not clear
whether this reflected a reduction in the numbers or in the
functional competence of EBV specific T-cells in the circulation
[14].
A further heterogeneous group of studies have looked at EBV
viral load dynamics during malaria exposure [15,16,17]. Compa-
rability of these results is difficult, as the assays have been conducted
on differing sample types, either whole blood, plasma alone or
PBMC preparations. Yone et al. saw significantly higher whole
blood viral loads in acute uncomplicated malaria cases compared to
convalescence, with a similar non-significant trend for complicated
malaria cases [17]. In the Gambia, PBMC EBV genome loads did
not differ between acute and convalescent malaria cases, but were
elevated in the cases compared to healthy controls [14].
Interestingly, the intensity of malarial infection in the Gambian
population has reduced substantially [18,19] since the conduct of
those earlier studies demonstrating impaired T-cell control of EBV
infection during acute malarial episodes [8,14]. We therefore set
out to re-examine these various parameters of EBV load and EBV-
specific CD8
+ T-cell immunity in these new circumstances. To do
so, we assayed EBV-specific CD8
+ T-cell responses using the two
functional assays (regression and IFN-c ELISPOT) that had been
used separately in earlier work [8,14], and for the first time also
enumerated the numbers of EBV epitope-specific cells by HLA
class I-peptide tetramer staining. Assays were conducted during
acute and convalescent stages of uncomplicated P. falciparum
infection in children aged 1–15 yrs and in healthy age- and sex-
matched control children without malaria.
Results
All malaria cases were both slide and PCR positive with a
geometric mean slide parasite density of 135,878/ul (95% CI
91,194–202,456). All controls were slide and PCR negative for P.
falciparum parasites. All of the malaria cases and all except one of
the controls who was excluded from the analyses were EBV
positive by IgG VCA ELISA. Consistent with previous findings
[12,14] there was a significant inverse correlation between EBV
genome load and age, Rho=20.3587, p=0.0440 (data not
shown). 84% of the children had at least one of the HLA
restrictions of interest (A2, B35, B8, B53).
Haematological indices, Malaria exposure and Cellular
frequencies in P. falciparum infected and uninfected
children
Table 1 shows that the two groups of infected and uninfected
children were similar with regard to age and sex, indicating
successful matching. As expected there was a significant decline in
haemoglobin level during the acute phase of malaria, which on
convalescence is not significantly different to that found in
uninfected controls.
Absolute CD4
+ and CD8
+ T-cell counts were significantly lower
during acute (Day 0) P. falciparum infection compared to
convalescence (Day 28) consistent with previous findings [20,21].
The total number of B-cells however did not significantly differ
between acute and convalescent samples or between infected (Day
0 or Day 28) and uninfected control children (Figure 1).
Table 1. Age, sex and haemoglobin levels of uncomplicated P.falciparum cases and aparasitaemic controls.
Acute
p.falciparum
Convalescent
p,falciparum
Aparasiteamic
Controls
Acute versus
Convalescent
1
Convalescent versus
Controls
2
Age (yrs) 7 (4.8–10.0) - 7 (4.5–9.5) - 0.95
Male:Female Ratio 1.91 - 2.00 - -
Haemoglobin (g/dl) 11.25 (9.83–12.63) 12.50 (11.40–12.93) 12.40 (11.65–13.20) 0.0038 0.65
For age and haemoglobin levels the median value and inter-quartile range are shown in brackets.
1p value calculated using Wilcoxon rank statistical comparison of matched pairs.
2p value calculated using Mann-Whitney U statistical comparison of unpaired data.
doi:10.1371/journal.pone.0031142.t001
Figure 1. Cellular frequencies in P. falciparum infected and
uninfected children. There is a significant decrease in the numbers of
CD3, CD8 and CD4 positive cells in acute uncomplicated P. falciparum
malaria (D0, circles), compared to cell numbers during convalescence in
the same donors (D28, triangles). The number of CD4 positive cells on
convalescence remains significantly lower than age- and sex- matched
healthy controls (squares). The number of CD19 positive B-cells doesn’t
significantly differ.
a P value calculated using Wilcoxon rank statistical
comparison of matched pairs.
b P value calculated using the Mann-
Whitney U comparison of unpaired data.
doi:10.1371/journal.pone.0031142.g001
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+ T-cell
responses did not significantly differ between P.
falciparum infected and uninfected children
In contrast to previous findings [14] we found no difference in
EBV genome loads between children with acute (Day 0) P.
falciparum malaria and age- and sex- matched healthy controls
(p=0.749). Likewise, the EBV genome loads did not change
significantly between D0 and D28 (p=0.2173) (Figure 2A).
Considering the number of B-cells remained constant (Figure 1)
it is unlikely that an increase in the total number of B-cells would
have obscured an increase in total EBV genome load. There were
7, 2, and 9 donors with undetectable viral loads in acute (D0),
convalescent (D28) and control groups respectively, although all
had a positive EBV serology.
Of the 84% of donors with appropriate HLA types for the lytic
peptide pool there were 7 (29%), 7 (30%) and 8 (31%) non-
responders in the acute (Day 0), convalescent (Day 28) and control
groups, respectively. Numbers of non-responders were of a similar
magnitude for the latent peptide pool, being 6 (25%), 9 (39%) and
8 (31%) for acute (Day 0), convalescent (Day 28) and control
groups, respectively. Background values were of a similar
magnitude in all groups, with medians of 15 SFU/10
6 PBMCs
in Day 0, 28 and control groups. Consistent with the observations
made for viral loads EBV-specific IFN-c ELISPOT counts didn’t
differ between children with acute (Day 0) P. falciparum malaria and
age- and sex- matched healthy controls to both lytic (p=0.096)
and latent (p=0.3738) peptide pools. Likewise, there was no
significant difference between Day 0 and Day 28 to both lytic
(p=0.9374) and latent (p=0.0998) peptide pools. (Figure 2B). The
results did not alter when all non-responders were excluded from
the analysis, when analysed without deduction of the background
values and when analysed taking into account the decline in
CD8% between Day 0 and Day 28 (Data not shown). Analysis of
these data looking at subgroups of different age ranges (0–7 yrs
and 8–15 yrs) also showed no significant differences in viral loads
and IFN-c ELISPOTs between Day 0 and Day 28 (Data not
shown). Figures 2C–E show that there was no significant difference
between the percentages of EBV-specific MHC Class I tetramer
positive cells during acute (Day 0) infection and age- and sex-
matched healthy controls (p=0.3599), consistent with our ELI-
SPOT findings. No significant difference was seen between Day 0
and Day 28 (p=0.4688).
To corroborate these findings we carried out regression assays
on cryopreserved PBMCs from a subset of acute uncomplicated
and severe P. falciparum infected children (n=9) during the
following malaria season. Consistent with our current EBV
genome, IFN-c ELISPOT and MHC Class I Tetramer data,
but in contrast to the original findings by Whittle et al. [8] we saw
no significant loss (p=0.5955) of regression during acute (Day 0) P.
falciparum malaria. These assays were conducted on cryopreserved
PBMCs but the magnitude of regressive capacity in acute (D0) P.
falciparum infected children did not significantly differ from those
detected using ex vivo assays on healthy control children
(p=0.2115, Figures 2F,G).
Programmed Death-1 (PD-1) expression in P. falciparum
infected and uninfected children
During acute P. falciparum infection the percentage of PD-1
expressing CD19
+ B-cells (p=0.04) and CD4
+ T-cells (p=0.0085)
was significantly higher than in convalescent samples
(Figures 3A,B). This trend remains when results are expressed
based on absolute numbers of CD19
+ B-cells (Figure 3C). During
acute P. falciparum malaria infection numbers of PD-1 expressing
CD19
+ B-cells (p=,0.0001) and CD4
+ T-cells (p,0.001) were
significantly higher than in healthy controls and during convales-
cence this number remained significantly higher than seen in the
controls.
Consistent with recent data [22], we found that during acute
disease (D0) CD38 expression, a marker of activation, significantly
correlated with PD-1 expression on CD8
+ T-cells (Spearman’s
correlation coefficient Rho=0.5018, p=0.0286, Figure 4A) and
also CD4
+ T-cells (Spearman’s correlations coefficient
Rho=0.4881, p=0.0399), supporting the hypothesis that PD-1
expression is associated with cellular activation and is not purely a
marker of functional exhaustion in these cells. However, this was
not found to be the case for CD19
+ cells (Spearman’s correlation
Rho=0.4298, and p=0.0663), data not shown.
Discussion
This work directly assesses the effect of acute P. falciparum
infection on the number and function of EBV-specific CD8
+ T-
cells ex vivo; in parallel with viral genome loads and traditional cell
culture-based techniques measuring T-cell mediated regression of
outgrowth of autologous B-cells. We show that the situation
currently in The Gambia is different to that reported earlier
[8,14], now, children with acute uncomplicated P.falciparum
malaria experience no elevation in EBV genome load in the
blood compared to age- and sex-matched healthy controls, nor do
they have any evidence of reduction in numbers or impairment of
function of their EBV-specific CD8
+ T-cells. We argue that these
different findings could be due to a recent decline in chronic
exposure to malaria in infancy and early childhood in the Gambia
[18,19].
Primary EBV infection, like Cytomegalovirus infection occurs in
early childhood in the Gambia [23] and more recent data
indicates that the age of EBV seroconversion continues to be low
with 87% of children between 14 and 18mths of age found to be
EBV seropositive in 2010 (S. Jayasooriya, unpublished data).
Loss of regression of EBV-infected B-cell outgrowth during
acute malaria was first demonstrated in Gambian children over 25
years ago [8], at a time when the entomological inoculation rate in
the country was several fold higher than the current day [24,25].
Furthermore, in 2003, Njie et al. detected high EBV loads from
PBMCs from Gambian children in the throes of acute malaria.
Interestingly these did not fall in convalescent samples taken six
weeks later but remained significantly higher than those detected
in a cohort of healthy control children, albeit not matched for age-
or sex in that report. In the present study, the EBV genome loads
(using the same assay as Njie et al.) from malaria cases, both in
acute and convalescent samples, are lower and not significantly
different from those of age and sex-matched controls, although
they remain significantly higher than the range typically seen for
healthy virus carriers in the UK population [14]. Notably, there
has been a considerable fall in malaria exposure in The Gambia
from 2003 onwards [18,19]. The likely difference in malaria
exposure between the cohorts used by Whittle et al. and Njie et al.
and the current study is highlighted by the dramatic change in
entomological inoculation rates from Brefet, a rural community
where part of the current study was based: 3.21 in 1991 to 0.62 in
2006 [24,25]. It therefore seems possible that at the time of these
earlier studies the life-long history of P. falciparum infection in
childhood was still sufficiently chronic/recurrent as to render the
EBV-host virus balance susceptible to modulation during a
renewed bout of acute malaria. By contrast, given the recent
decline in malaria incidence and increasing peak age of P.
falciparum related hospital admissions in the Gambia [18,19], it is
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falciparum infection. We would argue that a single, primary P.
falciparum infection is not sufficient to impair immunological
control of EBV infection.
The work by Moormann et al., who studied two cohorts with
differential malaria exposure in the Kisumu and Nandi areas of
Western Kenya, is relevant here. They noted higher EBV genome
loads in children, one to four years of age, living in areas
holoendemic for malaria compared to those only sporadically
exposed [12]. This is consistent with our data and supports the
idea that chronic repeated exposure to malaria throughout a
child’s early years is required to alter the EBV-host balance,
leading to high EBV loads and a greater likelihood of further
increases linked to acute malarial episodes. To investigate this
further would require following up children living in a holoen-
demic area from birth, to capture their first and subsequent
malaria episodes, and to longitudinally examine EBV-specific
immune responses and EBV viral loads.
Furthermore, we found that the function of EBV-specific CD8
+
T-cells as measured by IFN-c ELISPOT did not differ significantly
between malaria cases, in acute stage or convalescence, and age-
and sex- matched healthy controls. In a different study comparing
children living under differing malaria exposure in Kenya,
Moormann et al found that fewer children between five and nine
years of age responded to pools of EBV peptides when coming
from an area of high rather than sporadic malaria transmission
Figure 3. PD-1 expression is up-regulated on CD4 and CD19 positive cells during acute P. falciparum infection in children. A. Flow
cytometry plots demonstrating increased expression of PD-1 on CD4
+ T-cells (top row) and CD19 positive cells (bottom row) on Day 0 (black)
compared to Day 28 (white). B. The percentage of programmed death-1 (PD-1) expressing, CD4 and CD19 positive cells in acute uncomplicated P.
falciparum malaria infection (white box), on convalescence in the same donors (black box) and in age- and sex- matched healthy controls (grey box).
C. The absolute number of programmed death-1 (PD-1) expressing, CD4 and CD19 positive cells in acute uncomplicated P. falciparum malaria
infection (white box), on convalescence in the same donors (black box) and in age- and sex- matched healthy controls (grey box). All gates were set
using appropriate isotype controls.
a P values calculated using Wilcoxon rank comparison of matched pairs.
b p values calculated using Mann-Whitney
U statistical comparison of unmatched pairs.
doi:10.1371/journal.pone.0031142.g003
Figure 2. EBV genome loads and EBV-specific CD8
+ T-cell responses did not significantly differ between P. falciparum infected and
uninfected children. A, Epstein-Barr virus (EBV) genome loads during acute uncomplicated P. falciparum malaria infection (n=31), on
convalescence in the same donors (n=24), and from healthy age- and sex- matched controls (n=32). The median values, illustrated by the solid black
lines, for the groups were 253, 249 and 296 EBV copies/1610
6 peripheral blood mononuclear cells respectively. The dashed line represents the lower
limit of detection for EBV genomes in the assay. Donors below the dashed line had undetectable viral loads. B, Interferon-gamma (c)-enzyme linked
immunospot assays measured the responses to pools of lytic and latent EBV peptides in 27 donors with acute uncomplicated P. falciparum infection
(Day 0), on convalescence in 23 of the same donors (Day 28) and in 32 age- and sex-matched healthy controls. The solid black lines indicate the
median responses for each group. C, A flow cytometry plot from a representative donor (ID740) displaying MHC Class I Tetramer (B35 EPL) against
CD8
+ T-cells. D, The percentage of EBV MHC Class I Tetramer (B*35/EPL, A*2/GLC, A*2/CLG or B*8/RAK) positive CD8
+ T-cells in acute uncomplicated
P. falciparum infection (n=8), on convalescence in the same donors (n=8) and in age- and sex- matched healthy controls (n=10). E, The kinetics of
the paired MHC class I tetramer responses. F, Regression assays performed on cryopreserved peripheral blood mononuclear cells collected during
acute (open bars) and convalescent phases (filled bars) of uncomplicated and complicated P. falciparum malaria infection. The last two donors are
EBV seronegative controls. The median values in the acute and convalescent groups were 1.47 and 1.37 respectively (P=0.60). G, Ex vivo Regression
assays performed on healthy control children.
doi:10.1371/journal.pone.0031142.g002
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children makes it conceivable that the most pronounced difference
is detected in children above this age group. Of additional interest,
despite a preservation of EBV-specific CD8
+ T-cell responses, we
find that PD-1, a marker reported to signify cellular exhaustion, is
significantly up regulated in acute malaria and does not decline to
control levels by day 28. However, PD-1 expression significantly
correlates with CD38 expression on CD4
+ and CD8
+ T-cells
which supports recent findings in HIV that PD-1 is not purely a
marker of cell exhaustion [22] and reflects immune activation.
Our study has limitations that are worth discussion. Although
previously reported data suggest a dramatic decline in malaria
exposure in the country as a whole, our study design precludes
exact knowledge of the exposure history of our study participants.
However, we do know that 95% of three year old children
followed up longitudinally in a birth cohort adjacent to our study’s
catchment area had no serological evidence of malaria exposure
[18], and that a cohort study conducted in Brefet in the 2009
transmission season only identified one clinical case of malaria
[26]. In addition to this we found only 24% of control children,
mean age 7 years (range 1.5–16 years), were MSP-1(19)
seropositive (data not shown). This is lower than previously
quoted figures (30%, 0–7 years and 46%, 8–10 years) [27] Recent
publications from the Gambia from differing peri-urban sites also
confirm this decline [28], with one study demonstrating only a 4%
seropositivity to MSP-1(19) in 0 to 14 years olds in 2009 [19].
Previouscase-control studieshave demonstrated that acute malaria
infection can alter EBV host balance leading to an increase in EBV
genome loads [15,16,17]. The cross-sectional cohort studies
conducted by Moormann et al indicate that chronic malaria infection
also plays a role in tipping the balance in favour of the virus [11,12].
Our findings suggest that there is no impairment of EBV immunity
during a primary acute P. falciparum infection and therefore suggest
that alteration in EBV host balance is likely to be dependent on
cumulative prior infections. A further longitudinal study of primary
and cumulative acute P. falciparum infectionsandtheirimpactonEBV
host balance would be required to test this hypothesis.
Our findings, however, have more general implications adding
to the mounting evidence that the decline in malaria seen in some
parts of sub-Saharan Africa have wider implications than a
reduction in morbidity and mortality from malaria alone.
Additional changes have been seen in the rates of invasive
bacterial diseases such as non-typhoidal salmonella in the Gambia
[29,30], and all cause mortality in children within regions where a
reduction in malaria has been demonstrated [31]. Data to
establish whether our observation translates into a reduced
incidence of Burkitt’s lymphoma are needed.
Materials and Methods
Ethics Statement
The Gambian Government/ MRC Laboratories Joint Ethics
Committee approved this study. Participants were enrolled after
individual written informed consent was obtained from the
participant’s parent/guardian.
Donors
Thirty-two Gambian children (aged 1–15 years) enrolled into
studies of severe and uncomplicated malaria were tested [20]. All
presented with uncomplicated P. falciparum malaria, defined as a
temperature .37.5uC within the last 48 hours, and $5000
parasites/ml detected by slide microscopy. Thirty-two age- and
sex- matched healthy aparasitaemic controls were recruited from
Brefet, a rural community where malaria transmission has
dropped considerably [19]. All patients received standard care
according to the Gambian Government Treatment Guidelines.
P. falciparum infected children were bled on admission (D0) and
after 28 days (63 days); controls were bled at one time point.
500 ml of blood was collected into an EDTA microcontainer for a
full blood count (FBC) and DNA extraction. A further 4 mls was
collected into heparinised vacutainersH (BD). PBMCs were
separated on lymphoprep for use in ex vivo flow cytometric
surface staining and IFN-c ELISPOT assays.
Viral load
EBV genome loads were assayed by quantitative real-time PCR,
as described elsewhere [14,32,33]. The DNA extraction was
performed on 200 ml whole blood using the Qiagen, QIAmp DNA
Figure 4. PD-1 expression correlates with CD38 expression during acute uncomplicated P. falciparum infection. PD-1 expression is
shown on the y-axis and CD38 expression on the x- axis, each dot represents a single donor during acute (Day 0) uncomplicated P. falciparum malaria.
There is a significant correlation between CD38 and PD-1 expression on CD8
+ T-cells, A, and CD4
+ T-cells, B.
doi:10.1371/journal.pone.0031142.g004
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1610
6 PBMCs correcting for the PBMC percentage using the
haematology count.
Serology
IgG reactivity to EBV Viral Capsid Antigen (VCA) was
measured by a commercial ELISA kit (DeMeditech, DEEBV01).
HLA typing
Low resolution class I HLA typing was performed using
sequence-specific primers (SSP) for the HLA-alleles of interest,
A2, B35, B8 and B53, as previously described [34]. HLA-allele
selection was determined by frequency in the Gambian population,
determined by serological typing [35] and recently confirmed using
high resolution sequence typing (Louis-Marie Yindom, unpublished
data), and availability of known immunodominant EBV epitopes
restricted through these class I HLA alleles (table 2). Based on
polymorphisms in genes, some of which encode known CD8
+
epitopes, two types of EBV can be distinguished. Epitopes used in
this study have been defined based on work with type 1 EBV strains
in Caucasians. While we did not sequence the resident strains of
EBV in our donors, Njie et al. described previously that 90% of
Gambian donors they studied carried type 1 EBV [14] indicating
that the use of peptides derived from type 1 EBV is appropriate.
ELISPOT assays
IFN-c producing EBV specific lymphocytes were enumerated as
previously described using the ELISPOT technique [36]. PBMCs
were cultured in growth medium containing 10% human AB
serum. 96-well plates were pre-coated with anti-IFN-c mAb 1-
DIK (MABTECH, Stockholm, Sweden). Ex vivo responses in
growth medium, against EBV peptides (table 1), and PHA, both at
a final concentration of 5 mg/ml) were screened at 10
5 PBMCs per
well in duplicate. Plates were incubated overnight at 37uCa t5 %
CO2. The cells were discarded the following day, and a
biotinylated anti-IFN-c mAb, 7-B6-1 biotin (MABTECH), was
added at 1 mg/ml for 3 hours at room temperature, followed by
streptavidin-conjugated alkaline phosphatase (MABTECH) for
2 hours. Cytokine-producing cells were detected after a 30-min
reaction with 5-bromo-4-chloro-3-indolyl phosphate and nitro
blue tetrazoliym using an alkaline phosphatase-conjugate substrate
kit (Bio-Rad, Richmond, CA). Spots were counted using an
automated AID ELISPOT plate reader. PBMCs were screened
for reactivity to EBV using pools of commonly recognised CD8
+
lytic and latent peptides as shown in table 1 (obtained from the
Weatherall Institute for Molecular Medicine (WIMM), Oxford).
Negative control background values were subtracted from all
responses. Negative values were set to zero and classified as non-
responders.
Cell Surface and Tetramer Flow Cytometric Staining
Ex vivo, 1610
6 PBMCs per MHC Class I tetramer (for lower
cell counts all four tetramers were pooled) were stained for 1 hour
at 4uC in the dark. MHC class I Tetramers containing
GLCTLVAML (A2_GLC), CLGGLLTMV (A2_CLG),
EPLPQGQLTAY (B35_ EPL) and RAKFKQLL (B8_RAK)
peptides were used, conjugated to Phycoerythrin, PE, (A2_GLC
synthesised at the Institute for Cancer Studies, University of
Birmingham, the others from the WIMM). Tetramer staining was
followed by surface marker staining (30 min, 4uC in the dark)
according to the manufacturer’s protocol (BD Biosystems), using
the following antibodies: Programmed Death-1 (PD-1) Fluorescein
Isothiocyanate (FITC), CD4 PerCP, CD19 PE-Cy7, CD38
Allophycocyanin (APC), (BD Biosystems) CD8 Pacific Blue,
CD27 APC-Alexa750, (Ebioscience) CD28 ECD (Beckman
Coulter) and CD3 cascade yellow (Dako). Appropriate isotype
control antibodies, IgG1 FITC, IgG1 PerCP, IgG1 PE-Cy7, IgG1
APC, (BD Biosystems) IgG2a Pacific Blue, IgG1 APC-Alexa750,
(Ebioscience) and IgG1 Cascade Yellow (Dako), were used.
Samples were acquired on a Cyan
TM ADP flow cytometer using
Summit software (Beckman Coulter). Analysis was performed
using FlowJo (Tree Star Inc.) and isotype controls were used to set
the gating.
Regression Assays
These were carried out on cryopreserved PBMCs in the
following malaria season. PBMCs from uncomplicated and
complicated P. falciparum malaria cases recruited from the same
study platform [20] were used. In addition, we performed ex vivo
regression assays on healthy control children, recruited from Brefet
during the same year. Assays were performed as previously
described [9] except cells were seeded into U-bottom microtest
plates in doubling dilutions from 4610
4 to 1.2610
3 cells/well. The
strength of regression was expressed as the initial cell seeding
necessary to give a 50% incidence of regression among replicate
wells as calculated using the Reed-Muench formula.
Statistics
Viral genome load, serology, ELISPOT and flow cytometry
data were plotted and statistically analysed using GraphPad Prism
Table 2. EBV lytic and latent peptide pools.
EBV Protein Peptide Pool Epitope sequence Epitope co-ordinates HLA restriction
EBNA1 Latent HPVGEADYF 407–415 B53
EBNA1 Latent HPVGEADYFEY 407–417 B35
EBNA3A Latent QAKWRLQTL 158–166 B8
EBNA3A Latent YPLHEQHGM 458–466 B35
LMP2 Latent FLYALALLL 356–364 A2
LMP2 Latent CLGGLLTMV 426–434 A2
BRLF1 Lytic YVLDHLIVV 109–117 A2
BZLF1 Lytic EPLPQGQLTAY 54–63 B35
BMLF1 Lytic GLCTLVAML 280–288 A2
Note. – EBNA, Epstein-Barr Nuclear Antigen. LMP, Latency Membrane Protein.
doi:10.1371/journal.pone.0031142.t002
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Whitney U non-parametric tests were used for comparisons of
matched and unmatched data respectively. STATA (version 11)
was used to calculate Spearman’s rank correlation coefficients.
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